QuarterHawk — Equity ResearchQuarterHawk — Equity Research

InfuSystem Holdings, Inc. (INFU)

Healthcare

No action
Fundamental
3
Sentiment
2
Technical
4

Do Nothing: qualitativeScore is 2 (below the required floor of 3) with the shadow-compensation flag rendering false, and the 20-day average dollar volume of $2.08M is below the $5M liquidity floor; the chart is a genuine 52-week-high momentum breakout, but both a pullback limit toward EMA21 13.86 / SMA20 13.94 and a breakout buy-stop above the 15.325 swing high are pre-empted by these hard blocks, so no plan is issued.

Analysis as of 2026-11-11· more than 2 trading days ago

Company overview

InfuSystem Holdings, Inc. provides infusion pumps and related services across the U.S. and Canada through its Integrated Therapy Services and Durable Medical Equipment Services divisions. The company offers electronic ambulatory infusion devices and disposable kits for oncology and other medical needs, along with maintenance and repair services for various healthcare settings. Founded in 2005, its headquarters are in Rochester Hills, Michigan.

Fundamental

fair
Fundamental3
Mixed fundamentals

The company shows strong financial health but faces valuation concerns and revenue growth challenges.

Financially healthy but fully valued niche infusion-services company: double-digit returns on equity and invested capital, roughly 0.6x net leverage, $55M of undrawn revolver capacity, no debt maturities before 2030 and improving margins - offset by revenue growth that has slowed to low single digits, a lingering ERP-driven invoicing and receivables disruption, payer and oncology concentration, and discounted-cash-flow models that put modeled fair value well below the current quote.

Sentiment

weak
Sentiment2
Flat sentiment

Media and retail sentiment are neutral, with no significant catalysts or legal issues identified.

Dominant driver is a genuinely split Q3 2026 earnings print (2026-11-05, announced) — profit/EPS beat and net-income surge on one side, revenue shortfall plus ERP-driven collections delays on the other — so the catalyst is tagged neutral rather than bullish; the media delta is determinate but flat (aggregator polarity +0.10 baseline → +0.17 scoring, a move inside sample noise). A moderate red-flag cap applies for conflicting two-sided coverage (ceiling of 'mixed'), and since that ceiling is a maximum rather than a read, the setup lands lower: flat sentiment, a neutral trailing-only catalyst array, no forward-dated driver and unmeasured retail make this post-earnings digestion, not an actionable setup.

Technical

good
Technical4
Bullish breakout

The stock is in a bullish trend, reaching a new 52-week high, but liquidity constraints limit actionability.

Chart quality 4/5: a fully stacked bullish trend (price 15.28 above SMA20 13.94, SMA50 13.22, SMA200 10.51, EMA9 14.14, EMA21 13.86 and the daily VWAP 14.95), a fresh 52-week high at 15.325, a MACD bullish cross with the line above zero (0.29/0.24/+0.05) and ADX14 26.94 in trending territory together form a strong momentum-breakout/range-expansion chart; the single material weakness is short-term extension (Williams %R -1.51, RSI14 67.04) with ADX easing from 34.16 on 2026-10-28. The trade is nonetheless blocked before any plan is built: qualitativeScore 2 is below the required floor of 3 (shadow flag renders false, so no SHADOW_FST9 paper admission) and avgDollarVolume20 of $2.08M is below the $5M liquidity floor, so technicalScore is a chart-quality read only and the action is Do Nothing.

You’re looking at 2026-11-11 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.